AMRX vs CF · P/E 44, rev $2.79B vs P/E 12, rev $5.94B
Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) versus CF Industries Holdings Inc (CF) — a side-by-side from cached financials, not a winner call.
Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) is a drug manufacturers - specialty & generic company listed on NASDAQ.
CF Industries Holdings Inc (CF) is a agricultural inputs company listed on US.
Latest reported AMRX revenue for 2024-12-31 was $2.79B. Net income was -$73.9M. Revenue was up 16.7% from 2023-12-31 to 2024-12-31. AMRX currently screens at market cap $5.19B and trailing P/E 44.0.
Latest reported CF revenue for 2024-12-31 was $5.94B. Net income was $1.48B. Revenue was down 10.5% from 2023-12-31 to 2024-12-31. CF currently screens at market cap $14.98B and trailing P/E 12.2.
AMRX currently screens at market cap $5.19B and trailing P/E 44.0. CF currently screens at market cap $14.98B and trailing P/E 12.2.
Not investment advice. Open the AMRX and CF stock pages for the full models.
Not investment advice.